"We think we have an opportunity to make a difference in millions of lives," said Grimberg, part of Case Western Reserve School of Medicine's Center for Global Health and Diseases. "We may be able to license the technology in about a year. What we have to do is take this device into the field for point-of-care diagnosis. We have to show that it works, so that we can seek World Health Organization approval."
"This project is an excellent example of the way in which translational research at CWRU can make a difference in patient care," said Colin Drummond, director of the Coulter-Case Translational Research partnership within the Department of Biomedical Engineering. "It has taken years of hard work by Dr. Grimberg for this technology to reach the point where it was positioned to be translated into the market. It has been rewarding for the Coulter program to play a part in the translational phase of the project."
John R. Lewandowski, a recent Case Western Reserve engineering and management graduate, is DDG's co-founder and chief executive officer. His brother, Mark Lewandowski, a sophomore computer science and accounting student at the university, is DDG's chief financial officer.
The university's Technology Transfer Office, which supports faculty and student intellectual property and commercialization, has guided DDG to an innovation network, including such organizations as BioEnterprise and JumpStart.
Working with the Center for Global Health and Diseases and the Department of Infectious Diseases and HIV Medicine, Case Western Reserve is committed to licensing its medical discoveries, such as the RAM device, in ways that promote access and affordability in developing countries. As a result, the Universities Allied for Essential Medicines recently ranked Case Western Reserve the No. 1 Global Health research university in the United States.
|Contact: Marv Kropko|
Case Western Reserve University